S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
NYSE:NSPR

InspireMD (NSPR) Stock Forecast, Price & News

$1.64
-0.03 (-1.80%)
(As of 05/26/2023 ET)
Compare
Today's Range
$1.63
▼
$1.69
50-Day Range
$0.98
▼
$1.90
52-Week Range
$0.81
▼
$2.40
Volume
59,754 shs
Average Volume
221,983 shs
Market Capitalization
$13.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media

InspireMD MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
189.6% Upside
$4.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.17mentions of InspireMD in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$285,250 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.15 out of 5 stars

Medical Sector

996th out of 1,018 stocks

Surgical & Medical Instruments Industry

104th out of 105 stocks

See Top Rated MarketRank™ Stocks Here

NSPR stock logo

About InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Receive NSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter.

NSPR Stock News Headlines

May 25, 2023 | americanbankingnews.com
InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com
May 21, 2023 | americanbankingnews.com
InspireMD (NYSE:NSPR) PT Lowered to $4.75 at Alliance Global Partners
May 27, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
May 17, 2023 | americanbankingnews.com
InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka Purchases 175,000 Shares of Stock
May 17, 2023 | americanbankingnews.com
InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com
April 23, 2023 | americanbankingnews.com
InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com
April 15, 2023 | americanbankingnews.com
InspireMD (NYSE:NSPR) Receives New Coverage from Analysts at StockNews.com
March 29, 2023 | americanbankingnews.com
InspireMD (NSPR) to Release Quarterly Earnings on Thursday
May 27, 2023 | Behind the Markets (Ad)
"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
November 28, 2022 | benzinga.com
InspireMD Announces "12 Days of Carotid Stenting" Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists
November 11, 2022 | uk.finance.yahoo.com
InspireMD Third Quarter 2022 Earnings: Beats Expectations
November 8, 2022 | seekingalpha.com
InspireMD, Inc. (NSPR) Q3 2022 Earnings Call Transcript
November 8, 2022 | finanznachrichten.de
InspireMD, Inc.: InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update
November 8, 2022 | technews.tmcnet.com
InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update
November 8, 2022 | msn.com
Earnings Scheduled For November 8, 2022
September 15, 2022 | morningstar.com
InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference | Morningstar
September 8, 2022 | finance.yahoo.com
NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development
August 2, 2022 | finance.yahoo.com
InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update
June 9, 2022 | finance.yahoo.com
InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022
June 3, 2022 | stockhouse.com
InspireMD's CGuard(TM) Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022
May 10, 2022 | seekingalpha.com
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2022 Results - Earnings Call Transcript
May 10, 2022 | stockhouse.com
InspireMD Reports First Quarter 2022 Financial Results and Business Update
May 9, 2022 | seekingalpha.com
InspireMD Q1 2022 Earnings Preview
March 8, 2022 | finance.yahoo.com
InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results
March 7, 2022 | seekingalpha.com
InspireMD Q4 2021 Earnings Preview
See More Headlines
Receive NSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter.

NSPR Company Calendar

Last Earnings
3/30/2023
Today
5/27/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:NSPR
CUSIP
N/A
CIK
1433607
Web
www.inspiremd.com
Phone
9728887766804
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.75
High Stock Price Forecast
$4.75
Low Stock Price Forecast
$4.75
Forecasted Upside/Downside
+189.6%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,490,000.00
Net Margins
-349.45%
Pretax Margin
-348.92%
Return on Equity
-93.16%
Return on Assets
-69.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.81
Quick Ratio
3.42

Sales & Book Value

Annual Sales
$5.23 million
Price / Sales
2.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
1.02

Miscellaneous

Outstanding Shares
8,327,000
Free Float
7,509,000
Market Cap
$13.66 million
Optionable
Optionable
Beta
0.88

Key Executives

  • Marvin L. Slosman
    President, Chief Executive Officer & Director
  • Andrea Tommasoli
    Chief Operating Officer
  • Craig Shore
    Chief Financial Officer, Secretary & Treasurer
  • Juan Rigla
    Medical Director
  • Roei Samuri
    Vice President-Operations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













NSPR Stock - Frequently Asked Questions

What is InspireMD's stock price forecast for 2023?

0 brokerages have issued 12 month target prices for InspireMD's shares. Their NSPR share price forecasts range from $4.75 to $4.75. On average, they anticipate the company's share price to reach $4.75 in the next year. This suggests a possible upside of 189.6% from the stock's current price.
View analysts price targets for NSPR or view top-rated stocks among Wall Street analysts.

How have NSPR shares performed in 2023?

InspireMD's stock was trading at $0.8595 at the beginning of the year. Since then, NSPR stock has increased by 90.8% and is now trading at $1.64.
View the best growth stocks for 2023 here.

When is InspireMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our NSPR earnings forecast.

How were InspireMD's earnings last quarter?

InspireMD, Inc. (NYSE:NSPR) released its quarterly earnings results on Thursday, March, 30th. The company reported ($0.60) EPS for the quarter. The firm earned $1.03 million during the quarter. InspireMD had a negative net margin of 349.45% and a negative trailing twelve-month return on equity of 93.16%.

What other stocks do shareholders of InspireMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InspireMD investors own include Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA), Acasti Pharma (ACST), AcelRx Pharmaceuticals (ACRX), Acorda Therapeutics (ACOR), Aurora Cannabis (ACB) and Ambev (ABEV).

What is InspireMD's stock symbol?

InspireMD trades on the New York Stock Exchange (NYSE) under the ticker symbol "NSPR."

How do I buy shares of InspireMD?

Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InspireMD's stock price today?

One share of NSPR stock can currently be purchased for approximately $1.64.

How much money does InspireMD make?

InspireMD (NYSE:NSPR) has a market capitalization of $13.66 million and generates $5.23 million in revenue each year. The company earns $-18,490,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

How can I contact InspireMD?

InspireMD's mailing address is 4 MENORAT HAMAOR ST., TEL AVIV L3, 6744832. The official website for the company is www.inspiremd.com. The company can be reached via phone at 9728887766804 or via email at craigs@inspiremd.com.

This page (NYSE:NSPR) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -